Skip to Content

Tag: Eli Lilly


Eli Lilly says tirzepatide reduces OSA severity 

Specialty Providers

Eli Lilly says tirzepatide reduces OSA severity 

June 24, 2024HME News Staff

INDIANAPOLIS – Eli Lilly’s tirzepatide demonstrated a mean reduction of up to 62.8% on the apnea-hypopnea index (AHI), or about 30 fewer events restricting or blocking a person's airflow per hour of sleep, compared to placebo, according to the company’s SURMOUNT-OSA phase 3 clinical trials evaluating the drug for the treatment of moderate-to-severe obstructive sleep apnea in adults with obesity, with and without CPAP therapy.  In a key secondary endpoint, the company...

CPAP Therapy, Eli Lilly, Obstructive Sleep Apnea (OSA), Tirzepatide


Read Full Articlered right arrow icon

Also Noted

Glooko, Eli Lilly to collaborate on connected insulin pens

May 7, 2021HME News Staff

GOTHENBURG, Sweden – Glooko will partner with Eli Lilly for a strategic digital health collaboration using Eli Lilly’s connected insulin pens, the Tempo Pen and Tempo Smart Button. Through the agreement, the Tempo Smart Button will pair with Glooko’s software to integrate personalized health care data from the Tempo Pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers and food logs. “Lilly is...

Eli Lilly, Glooko, Insulin pen


Read Full Articlered right arrow icon